Eli Lilly CEO says Medicare price negotiations could harm drug development

Eli Lilly CEO David Ricks said Medicare price negotiations could potentially harm drug development.
He referred to a provision in the Biden administration’s Inflation Reduction Act that will allow the Medicare program to negotiate prices on the costliest prescription drugs each year.